CEACAM5 and neoplasm: Based on patient’s IHC results with a high expression level of PD-L1 in tumor cells (50%) and immune cells (3%), three cycles of chemotherapy combined with immunotherapy (sintilimab 200 mg IVGTT D1) were decided to perform, resulting in a partial response with decreased tumor size and CEA level (11).